Evofem Biosciences, Inc. entered into a License and Supply Agreement with Windtree Therapeutics on March 20, 2025, and amended its merger agreement on March 22, 2025, changing the merger completion date to September 30, 2025, and requiring a $1.5 million investment by April 7, 2025.